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Abstract
Anti-angiogenic therapies have demonstrated their value in the
setting of advanced cancer, and are being explored for use in
micrometastatic disease. Recent preclinical studies suggest that
adjuvant anti-vascular endothelial growth factor (VEGF) therapies
may increase the risk of metastasis. How concerning are these
preclinical studies, and should they affect our willingness to
explore anti-VEGF therapy in the adjuvant setting?
Background
The anti-vascular endothelial growth factor (anti-VEGF)
therapy bevacizumab was approved for metastatic breast
cancer based upon two randomized controlled trials, E2100
and AVADO, that randomized women to receive taxane
therapy alone or in combination with bevacizumab for HER2-
negative metastatic disease [1,2]. Both trials demonstrated a
significant improvement in progression-free survival; neither
demonstrated an improvement in overall survival, though both
were poorly powered. Other phase II trials suggest benefit
from the combination of anti-VEGF therapies with anti-HER2
therapies [3,4].
Based upon these results, adjuvant trials have begun in
HER2-negative and HER2-positive populations. E5103
randomizes women with HER2-negative disease to receive
either chemotherapy (ACT - doxorubicin, cyclophosphamide,
and paclitaxel) alone or in combination with bevacizumab
(administered either concurrently with chemotherapy or for a
year). BETH randomizes HER2-positive patients to receive
either a standard chemotherapy/trastuzumab combination or
the same with bevacizumab. Both are large, well-powered
trials with primary disease-free survival endpoints and
secondary overall survival endpoints.
The Article
It is against this backdrop that the work of Ebos and
colleagues [5] should be considered. They examined the
small molecule receptor tyrosine kinase inhibitor sunitinib as
adjuvant therapy in a mouse human tumor xenograft model of
breast cancer, 231/LM2-4LUC+. They demonstrated that
short-term (7 day) administration of sunitinib, either before or
after tail vein inoculation, accelerated metastasis and impaired
survival. Similar results were obtained in a 231/LM2-4LUC+
spontaneous model of metastasis. A human melanoma
xenograft model also gave generally similar results, though a
murine melanoma syngeneic model revealed what were said
to be ‘biphasic effects, with about half of the mice
progressing with accelerated metastasis and the remainder
showing a prolongation in survival.’ Sustained sunitinib
therapy, in contrast to short-term therapy, decreased primary
tumor growth without improving metastasis-related survival.
The same authors, in previous work, have demonstrated that
treatment with anti-VEGF agents is associated with host-
related increases in several cytokines, including osteopontin,
granulocyte colony-stimulating factor, and SDF1a [6]. The
current work does not address the role of drug-induced
cytokine production, nor the possibility of rebound re-growth
of blood vessels documented by other investigators in the
laboratory [7] or the clinic [8] following cessation of anti-
VEGF agents.
The Viewpoint
These provocative findings [5] (and similar work by Pàez-
Ribes and colleagues [9]) suggest that in trying to do good
with adjuvant anti-VEGF therapy we might create the great
harm of increasing distant metastatic disease. How con-
cerned should we be?
All preclinical model systems have limitations and should be
viewed with caution. Model systems such as the
231/LM2-4LUC+ model employed by Ebos and colleagues
are beloved by investigators because they reproducibly
metastasize in quicksilver fashion [5]. The clinic is different:
patients (and their tumors) are heterogenous, metastasize to
multiple organs, and develop overt metastasis over years. In
addition, anti-VEGF agents demonstrate benefits across
multiple cancer types. The macrometastatic setting has been
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our best predictor of success in micrometastatic disease.
While nothing is impossible, it seems unlikely that benefits
seen in advanced disease will suffer a complete reversal of
fortune in the curative setting.
These findings do raise critical issues regarding adjuvant anti-
VEGF therapy. While unlikely to cause decrements to an
entire population, it is possible that subgroups will experience
inferior outcomes. In the study by Pàez-Ribes and colleagues
[9], differences in invasiveness were seen in RIP1-Tag2/
Cre;Vegf-Afl/fl mice (b-VEGF-KO) when compared to b-
VEGF-WT. These findings demonstrate that inherited (not
mutational) variability is important in the angiogenic pheno-
type and affects outcome. Robust genetic variability occurs in
genes controlling human angiogenesis, which may affect
outcomes with anti-angiogenic therapies. In E2100, patients
with VEGF -2578AA and -1154AA genotypes had prolonged
overall survival but no difference in progression-free survival
[10]. This may suggest an interaction between genotype and
outcome after cessation of therapy, and that some subgroups
experience unfavorable changes in the angiogenic milieu.
Another major issue is the proper duration of anti-angiogenic
therapy. Unlike the ‘patients’ treated by Ebos and colleagues
[5], adjuvant therapy patients receive far more than a week’s
work of sunitinib. Patients regularly receive adjuvant chemo-
therapy, adjuvant hormonal therapy (if estrogen receptor-
positive) and trastuzumab (if HER2-positive). These therapies
provide significant survival benefits, but more importantly
synergize with anti-VEGF therapies in multiple preclinical
models. Sunitinib monotherapy is the last thing one would
attempt in the adjuvant setting, and 7 days of anti-VEGF
therapy contrasts with anti-VEGF adjuvant trials administering
from months to a year of anti-VEGF therapy.
So how worried should we be? Clinical trialists are always
worried, and with good cause: trials routinely go wrong for
multiple and unpredictable reasons. Duration in particular may
be a concern in the adjuvant setting. Some adjuvant therapies
(chemotherapy and trastuzumab) require fairly short durations
of therapy, but others (for example, hormonal therapy) require
years to maximize benefit. We simply do not know how long
we will need to administer adjuvant anti-VEGF therapy.
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